Sodium restriction in CKD: pressure changes in a 20-person crossover trial
LowSALT CKD measured blood pressure, fluid and urinary markers rather than long-term kidney failure.

Illustrative food image, not a photograph of the study intervention.
The trial population matters
The LowSALT CKD phase 1 trial enrolled 20 adults with hypertension and stage 3–4 chronic kidney disease. It used a double-blind, placebo-controlled randomized crossover design to compare higher and lower sodium intake. This was a small intervention study in a defined clinical population, not a survey of salt habits in the general public. Its design strengthens the comparison of the sodium conditions, while its size limits how broadly the results can be applied. The abstract itself calls for larger studies and longer intervention times. Those limitations belong alongside the findings, particularly when a study concerns people with established kidney disease.
McMahon EJ, Bauer JD, Hawley CM, Isbel NM et al.. J Am Soc Nephrol, 2013. PMID 24204003 · DOI
Pressure fell under the lower-sodium condition
Salt restriction produced a mean reduction of 10 mm Hg in systolic pressure and 4 mm Hg in diastolic pressure. The reported 95% confidence intervals were 5 to 15 mm Hg for the systolic reduction and 1 to 6 mm Hg for the diastolic reduction. The study assessed ambulatory blood pressure, not simply a dietary preference or self-reported impression. These are group results from 20 people with hypertensive stage 3–4 CKD. They should not be represented as a guaranteed pressure response, a universal sodium target, or evidence that every person with kidney disease has the same requirements.
McMahon EJ, Bauer JD, Hawley CM, Isbel NM et al.. J Am Soc Nephrol, 2013. PMID 24204003 · DOI
Fluid and urinary markers added context
Beyond blood pressure, salt restriction reduced extracellular fluid volume, albuminuria and proteinuria. The protocol also assessed renin and aldosterone levels and measures of arterial stiffness, including pulse wave velocity and augmentation index. The abstract does not report a numerical treatment effect for every measured variable, so a summary should not imply that all endpoints improved. The positive findings establish a signal across several physiological and urinary measures in this particular trial. They do not establish that fewer participants needed dialysis, experienced cardiovascular events or died; those are different outcomes from the pressure, fluid and urinary changes described here.
McMahon EJ, Bauer JD, Hawley CM, Isbel NM et al.. J Am Soc Nephrol, 2013. PMID 24204003 · DOI
A clinical signal without a universal menu
The authors interpreted the findings as support for sodium restriction in CKD management, while explicitly requesting larger and longer studies. That combination is important: a clinically relevant marker response can justify further attention without resolving long-term outcomes. The participants' stage 3–4 CKD and hypertension are central to interpreting the average 10/4 mm Hg pressure reduction. The abstract does not provide a general-purpose recipe plan or demonstrate that a particular home-cooked meal reproduces the result. This article therefore offers no paired recipes, sodium prescription or medication changes. Its scope is to explain what this controlled comparison found and what it did not establish.
McMahon EJ, Bauer JD, Hawley CM, Isbel NM et al.. J Am Soc Nephrol, 2013. PMID 24204003 · DOI